Synthomer Raises Outlook Amid Strategic Pivot and Divestment Momentum
H1 2026 delivers strong margins and free cash flow guidance; premium on self-help and portfolio reshaping.
SYNT.L · Earnings Call · 2026-08-04
A Half Ahead of Expectations
Synthomer's first-half 2026 results landed well ahead of market expectations, lifting revenue 5% in constant currency, EBITDA 13%, and EBIT 36% year-on-year. The company used its call to reset the narrative from a leveraged base-chemicals name to a focused specialty player. CEO Michael Willome opened with a clear message: “We are today raising our outlook for the full year.” — Michael Willome, CEO · 2026-08-04 This guidance upgrade rests on recurring strategic progress and disciplined self-help—not on the temporary tailwind from the Iran conflict. The data center boom stands out as a genuine growth engine. Intumescent coatings for AI data centers and infrastructure projects doubled volumes in the period, while new applications in medical nonwovens and onshore drilling extended the specialty reach. These are not cyclical base-chemical wins; they are self help initiatives that compound into a more durable earnings profile.
Portfolio Reshaping and Deleveraging
The divestment program is accelerating. The sale of Acrylate Monomers—due to close in September—removes a capital-intensive cyclical business. Management confirmed three further divestments in progress, targeting GBP 150–200 million of proceeds. CFO Iain Torrens noted that EBITDA growth and capex discipline will do the heavy lifting on deleveraging: “If you take the numbers … suddenly this GBP 25 million, GBP 30 million becomes GBP 75 million, GBP 80 million.” Free cash flow is now guided to be positive for the full year, and covenant leverage should fall to 4.0–4.35x by year-end from 4.9x in June. The “EBITDA for the continuing business has increased by GBP 14 million versus the prior period” — Iain Torrens, Interim CFO · 2026-08-04, even after absorbing wage inflation and bonus normalization.
Market Disruption: A Temporary Boost, Not a New Baseline
The Iranian conflict created a temporary arbitrage for Synthomer's nitrile (NBR) business as some Asian competitors struggled with feedstock. Willome gave a concrete example of the volatility: “The margin in January and February was on NBR, especially, was $180 per ton, went up to $600 and is down now to $250 to $300.” — Michael Willome, CEO · 2026-08-04 These Q2 gains are not expected to repeat in H2, underscoring the company's conservative outlook. But the episode validated the resilience of its raw material procurement and pass-through pricing capabilities—qualities that matter in a volatile global chemical market. As Willome put it, “we had since 4 years an uplift in gross margin of 600%” when reflecting on the margin trajectory, a testament to the strategic shift.
Financial Discipline and Free Cash Flow
The balance sheet remains the priority. With the refinancing completed in April and a runway to 2029, Synthomer is now using lower-cost factoring to diversify funding, although management was careful to strip its impact from the free cash flow narrative. The H1 working capital outflow was higher as raw material prices surged, but inventory volumes fell 8% year-on-year. The company expects a strong second-half seasonal reversal, supporting its improved free cash flow guidance. Between divestments, EBITDA growth, and reduced capex (GBP 70 million this year, down from GBP 86 million in 2025), Synthomer is crafting a credible path to cut leverage by a full turn within 12 months—a signal that the transformation is no longer just a strategy slide, but a delivered plan.